Skip to Content
  • Article
  • Open Access

17 November 2026

13 Pages

Is the Answer in the Biopsy? Predicting 12-Month RRT Outcomes in Renal Thrombotic Microangiopathy

,
,
,
,
,
,
,
,
…
1
Centro de Referencia CSUR para Patología Glomerular Compleja, Nephrology Department, Hospital Universitari Vall d’Hebron, 08035 Barcelona, Spain
2
Facultat de Medicina, Universitat Autònoma de Barcelona, 08193 Cerdanyola del Valles, Spain
3
Grup de Nefrologia i Trasplantament Renal, Vall d’Hebron Institut de Recerca, 08035 Barcelona, Spain
4
Pathology Department, Hospital Universitari Vall d’Hebron, 08035 Barcelona, Spain

Abstract

The prognostic value of quantitatively assessed histologic lesions in biopsy-proven renal thrombotic microangiopathy (TMA) remains poorly defined. We retrospectively evaluated 37 adults with biopsy-proven renal TMA to identify clinical and histologic predictors of renal replacement therapy (RRT) dependence at 12 months. At presentation, 18 patients (48.6%) required RRT, and 17 (45.9%) remained RRT-dependent at 12 months. Patients with persistent RRT dependence had higher peak serum creatinine (sCr) (8.97 ± 3.91 vs. 4.78 ± 2.20 mg/dL; p < 0.001) and greater proteinuria at diagnosis (5828 vs. 1365 mg/g; p = 0.004). Peak sCr showed the strongest discrimination for 12-month RRT dependence (AUC 0.815; cutoff 7.6 mg/dL). Among histologic variables, global glomerulosclerosis showed the best discrimination (AUC 0.725; cutoff ≥ 8%), whereas other TMA-associated lesions had limited prognostic value. In multivariable analysis, both peak sCr (OR 1.74, 95% CI 1.16–2.62; p = 0.008) and global glomerulosclerosis ≥ 8% (OR 8.76, 95% CI 1.23–62.40; p = 0.030) were independently associated with 12-month RRT dependence. Adding global glomerulosclerosis ≥ 8% significantly improved model fit compared with peak sCr alone (likelihood-ratio test, p = 0.016), increasing the apparent AUC from 0.815 to 0.868.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.